The community is delayed by three days for non registered users.

TIL--InStil Bio. A company I've

Posted by shellson2 on 13th of Feb 2025 at 04:53 pm

TIL--InStil Bio. A company I've been holding for a little while now--had a good day today on positive trial news, up 24%. What I find most interesting is the analyst PT's

(The Baird is now 5 months old, but hefty nonetheless). 

The stock was once in $80's last Fall.

Baird

Reiterates

Outperform


$180

16/09/2024 ET

Jefferies

Upgrades

Buy


$52

07/01/2025 ET

HC Wainwright & Co.

Reiterates

Buy


$110

18/11/2024 ET


WGS--GeneDx

GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for March 3, 2025 at 4:30 P.M. Eastern Time

TEM--Tempest, new 52 week-r

Posted by shellson2 on 13th of Feb 2025 at 10:38 am

TEM--Tempest, new 52 week-r

HIMS--big pop up (lol). 10+%

Posted by shellson2 on 13th of Feb 2025 at 09:49 am

HIMS--big pop up (lol). 10+%

Up 15%, way above volume

SENS--EU compliance may be next trigger for stock

Eversense 365 is the world's first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of the same year.

The Eversense 365 CE Mark submission was prepared in compliance with the EU Medical Device Regulation (MDR) and, upon approval, would enable the commercialization of Eversense 365 in European Union (EU) member countries by Senseonics' commercial partner, Ascensia Diabetes Care. Following CE Mark approval in Europe, the Company plans to distribute the Eversense 365 System in Germany, Italy, Spain (including Andorra), Poland, Switzerland and Sweden.

"Completing the CE Mark submission for Eversense 365 brings us a step closer to improving lives and health outcomes for patients in Europe. Given the success we have had to date with the US launch of Eversense 365 by our partner, Ascensia, we look forward to the opportunity to offer a ‘once a year' solution for glucose control to the millions of people living with diabetes in the European Union," said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics.

SENS--

New 52wk today, vol is above average. Their next business update could be very meaningful. Will dig for that info.

EH—new hi’s, up 18%. Could just be getting started.

HSAI--picked this up recently, has

Posted by shellson2 on 12th of Feb 2025 at 09:14 am

HSAI--picked this up recently, has hit new hi's. China LiDAR space.

UPST--Didnt play it...up 15%

SMCi see-sawing

UPST too. Wild one

The Meta streak is one

Posted by shellson2 on 11th of Feb 2025 at 03:27 pm

The Meta streak is one for the ages...todays move is on half volume. Maybe inflation data will have them getting on the elevator this week

NOTE--another leg up. Over 2.15

Posted by shellson2 on 11th of Feb 2025 at 01:38 pm

NOTE--another leg up. Over 2.15 its gets very interesting

ATAT--large Chinese hotel operator. Should

Posted by shellson2 on 11th of Feb 2025 at 12:46 pm

ATAT--large Chinese hotel operator. Should move with the up trending market over there. 

Bonds up less than I

Posted by shellson2 on 11th of Feb 2025 at 12:41 pm

Bonds up less than I expected so far...

picked up some down at $70

If this is correct, then they have 4 months of cash on hand. Credit--BioPharm Catalyst

cash on hand--6.6mm

Offering will come soon I bet

Newsletter

Subscribe to our email list for regular free market updates
as well as a chance to get coupons!